LO shedding is common to several tumor types, including prostate, breast, bladder, lung cancer, and other tumors ([38] and unpublished observations) and is enhanced by silencing of the gene encoding the cytoskeletal regulator Diaphanous related formin-3 (DIAPH3), or by activation of the epidermal growth factor receptor (EGFR) and overexpression of a membrane-targeted, constitutively active form of Akt1. Here, EGFR is linked to lung cancer.